Trafalgar International (GCAN) Return on Capital Employed (2018 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Return on Capital Employed of 22.29% for Q1 2026, up 549.0% year-over-year from 3.43% in Q1 2025, and down 10.91% quarter-over-quarter from 25.02% in Q4 2025.
Trafalgar International (GCAN) Return on Capital Employed (2018 - 2026) Analysis & Trends
Greater Cannabis Company's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 22.29% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 549.0% year-over-year to 22.29%; the TTM figure through Mar 2026 stood at 22.29% (up 549.0% YoY), while the FY2025 annual figure was 25.66%, up 570.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 22.29%, down from 25.02% in the prior quarter.
- The five-year high for Return on Capital Employed was 48.98% in Q1 2022, with the low at 15.09% in Q3 2025.
- The 5-year median for Return on Capital Employed is 25.47% (2024), against an average of 27.67%.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed tumbled 9665 bps in 2022, then surged 636 bps in 2025.
- Greater Cannabis Company's Return on Capital Employed stood at 33.11% in 2022, then retreated by 18 bps to 27.22% in 2023, then sank by 31 bps to 18.67% in 2024, then surged by 34 bps to 25.02% in 2025, then dropped by 11 bps to 22.29% in 2026.
- Business Quant data shows GCAN's Return on Capital Employed at 22.29% in Q1 2026, 25.02% in Q4 2025, and 15.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | 22.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.29% |
| Dec 31, 2025 | 25.02% |
| Sep 30, 2025 | 15.09% |
| Jun 30, 2025 | 15.99% |
| Mar 31, 2025 | 16.81% |
| Dec 31, 2024 | 18.67% |
| Sep 30, 2024 | 20.66% |
| Jun 30, 2024 | 23.80% |
| Mar 31, 2024 | 25.47% |
| Dec 31, 2023 | 27.22% |
| Sep 30, 2023 | 27.59% |
| Jun 30, 2023 | 27.51% |
| Mar 31, 2023 | 30.11% |
| Dec 31, 2022 | 33.11% |
| Sep 30, 2022 | 46.36% |
| Jun 30, 2022 | 45.67% |
| Mar 31, 2022 | 48.98% |
| Dec 31, 2021 | 83.56% |
| Sep 30, 2021 | 117.28% |
| Jun 30, 2021 | 142.32% |